Mabrouk T, Ellis R W
Shire Biologics Inc., Laval, Quebec, Canada.
Dev Biol (Basel). 2002;110:125-34.
Influenza vaccines have been produced for decades in eggs by a classical technology. A range of new vaccine technologies and approaches has been applied to improving these vaccines. Foremost among these are the use of mammalian cells to produce influenza viruses, the use of new adjuvants, and a live attenuated vaccine. Mammalian cell-derived vaccines, produced in nontumorigenic cell lines, have been developed and shown to be effective production systems as alternatives to eggs. This manuscript discusses the advantages and challenges of mammalian cell production, as well as alternative technologies for influenza vaccines.
几十年来，流感疫苗一直采用传统技术在鸡蛋中生产。一系列新的疫苗技术和方法已被应用于改进这些疫苗。其中最重要的是利用哺乳动物细胞生产流感病毒、使用新型佐剂以及一种减毒活疫苗。在非致瘤细胞系中生产的哺乳动物细胞衍生疫苗已得到开发，并被证明是替代鸡蛋的有效生产系统。本文讨论了哺乳动物细胞生产的优势和挑战，以及流感疫苗的替代技术。
